Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001104659-26-126285
On November 12, 2026, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the three months ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $18.93M | $17.03M | $14.63M | $15.28M |
| Net Income | -$1.32M | -$2.32M | -$2.39M |
Journey Medical Corp · CIK 1867066 · Engraved from SEC EDGAR
| $16.79M |
| EPS Diluted | -$0.05 | -$0.09 | -$0.12 | $0.80 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Journey Medical reported total revenues of $19.0 million for the third quarter of 2026, an 8% increase from $17.6 million for the third quarter of 2025.¶2
Gross margin was 69% for the third quarter of 2026, compared to 67% for the prior-year quarter, while SG&A was $12.6 million, including a one-time $1.7 million vendor dispute expense.¶3¶4
The GAAP net loss narrowed to $1.3 million, or $(0.05) per share, for the third quarter of 2026, compared to a net loss of $2.3 million, or $(0.09) per share, for the third quarter of 2025.¶5
At September 30, 2026, the Company had $22.3 million in cash and cash equivalents, compared to $24.1 million at December 31, 2025.¶6